NCT06847464View on ClinicalTrials.gov

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

May 24, 2025

Study Completion Date

June 1, 2025

Conditions
RSV InfectionDrug Drug Interaction (DDI)
Interventions
DRUG

EDP-323

Subjects will receive EDP-323 on Days 1 and 14

DRUG

Itraconazole

Subjects will receive itraconazole QD Days 5-18

DRUG

EDP-323

Subjects will receive EDP-323 on Days 1 and 23

DRUG

carbamazepine

Subjects will receive carbamazepine on Days 5 - 27

DRUG

EDP-323

Subjects will receive EDP-323 on Days 1 and 8

DRUG

Quinidine

Subjects will receive quinidine on Days 5-12

DRUG

EDP-323

Subjects will receive EDP-323 on Days 1 and 14

DRUG

fluconazole

Subjects will receive fluconazole on Days 5-18

Trial Locations (1)

78209

ICON, plc, San Antonio

Sponsors
All Listed Sponsors
lead

Enanta Pharmaceuticals, Inc

INDUSTRY

NCT06847464 - A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. | Biotech Hunter | Biotech Hunter